VIVUS raised $202.5 million in its follow-on offering at $22.50 per share. Needham acted as a co-manager on the transaction. The net proceeds from the sale of the shares from the offering will be used by VIVUS to fund the creation of the infrastructure including the hiring of a field sales force and the development and production of promotional materials necessary to commercialize Qnexa in the United States, if approved, for the treatment of obesity; to cover expenses in connection with pursuing non-U.S. marketing approvals for Qnexa and avanafil; to fund new clinical trials for Qnexa and other investigational product candidates; to finance our marketing and awareness efforts for Qnexa; to fund the ongoing hiring of additional sales and marketing, regulatory, medical affairs and research and development and other personnel to support Qnexa and our other investigational product candidates; to fund additional investment in information technology infrastructure and product support systems; for third-party contract supply costs; to fund the cost of any post-approval Qnexa requirements, including the cost to complete a cardiovascular outcomes study and any additional studies required for Qnexa; and for general corporate purposes, including working capital. The Company may also opt to use a portion of the net proceeds to acquire strategic assets.
VIVUS (NASDAQ: VVUS) is a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health.